Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 8/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980975 | 1.00 | OPRL1 (0.43) | OPRL1ADRA1AMCHR1HRH3SIGMAR1 | |
| SCHEMBL4977503 | 0.92 | OPRL1 (0.51) | OPRL1HRH3OPRM1KCNH2 | |
| SCHEMBL4977509 | 0.92 | OPRL1 (0.51) | OPRL1HRH3OPRM1KCNH2 | |
| SCHEMBL4977726 | 0.91 | OPRL1 (0.47) | OPRL1ADRA1AMCHR1HRH3AVPR1A | |
| SCHEMBL4977724 | 0.91 | OPRL1 (0.47) | OPRL1ADRA1AMCHR1HRH3AVPR1A | |
| SCHEMBL4978226 | 0.90 | OPRL1 (0.47) | OPRL1ADRA1AMCHR1HRH3 | |
| SCHEMBL4978220 | 0.90 | OPRL1 (0.47) | OPRL1ADRA1AMCHR1HRH3 | |
| SCHEMBL4977875 | 0.88 | OPRL1 (0.55) | OPRL1ADRA1AMCHR1HRH3AVPR1A | |
| SCHEMBL4977880 | 0.88 | OPRL1 (0.55) | OPRL1ADRA1AMCHR1HRH3AVPR1A | |
| SCHEMBL4977524 | 0.86 | OPRL1 (0.45) | OPRL1ADRA1AMCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | OPRL1, OPRD1, OPRK1 | OPRL1 1/4885ADRA1A 121/4885MCHR1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.